Principles of treatment: After about one year of effective hormone therapy for prostate cancer, most of them develop drug resistance and recurrence of metastasis, which is called hormone non-dependent prostate cancer. There are two types of such cases. 1. Non-androgen-dependent prostate cancer, where endocrine therapy is effective, and after a period of time (15 – 30 months), the PSA rises or clinical symptoms appear. Although this type of patients appear to be resistant to endocrine therapy and relapse, there are still some cases in which second-line endocrine drug therapy is effective. 2. Hormone-refractory prostate cancer, which is ineffective to second-line endocrine drug therapy, has elevated PSA three times in a row at two-week intervals. Or PSA progresses during second-line treatment, or PSA and metastasis progresses after retreating from anti-androgen therapy for more than four weeks, it is hormone-refractory prostate cancer. Treatment strategy: I. Drug depot treatment: to maintain testosterone level